Solutia Reports Third Quarter 20...(g Comparability ...)

Date:10/26/2009

g Comparability SOLUTIA INC. CONSOLIDATED STATEMENT OF OPERATIONS (Dollars and shares in millions, except per share amounts) (Unaudited) Successor --------- Three Months Three Months Ended Ended September 30, September 30, 2009 2008 ------------- ------------- Net Sales $448 $587 Cost of goods sold 312 431 --- --- Gross Profit 136 156 Selling, general and administrative expenses 53 75 Research, development and other operating expenses, net 8 3 --- --- Operating Income 75 78 Interest expense (31) (42) Other income (loss), net (1) 4 --- --- Income from Continuing Operations Before Income Tax Expense 40 43 Income tax expense 12 17 --- --- Income from Continuing Operations 31
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009